


CLAIMS

What is claimed is:

1. A method of treating or suppressing an Adenoid Cystic Carcinoma (ACC) tumor in a subject comprising the step of administering to said subject a composition comprising one or more
 5 compounds represented by the structure of Formula (III):



or prodrugs or salts thereof; wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;


10 R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

R₃ is H or -CH₃;

each R_a is independently F, Cl, -CN, -OCH₃, and/or -NHCH₂CH₂OCH₃; and

y is zero, 1, or 2.

- 15 2. A method of inhibiting tumor growth in a subject with an Adenoid Cystic Carcinoma (ACC) tumor comprising the step of administering to said subject a composition comprising one or more compounds represented by the structure of Formula (III):



20 or prodrugs or salts thereof; wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

R₃ is H or -CH₃;


each R_a is independently F, Cl, -CN, -OCH₃, and/or -NHCH₂CH₂OCH₃; and

y is zero, 1, or 2.


3. The method of any one of claims 1-2, wherein:
 - 5 R₁ is -CH₂CF₃ or -CH₂CH₂CF₃; and
 - R₂ is -CH₂CF₃ or -CH₂CH₂CF₃.
4. The method of any one of claims 1-3, wherein:
 - y is zero or 1.
5. The method of any one of claims 1-4, wherein:
 - 10 R₁ is -CH₂CH₂CF₃; and
 - R₂ is -CH₂CH₂CF₃.
6. The method of any one of claims 1-5, wherein:
 - y is zero.
7. The method of any one of claims 1-6, wherein said compound comprises: (2R,3S)—N-
 - 15 ((3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (1); (2R,3S)—N-((3S)-2-Oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (2); (2R,3S)—N-((3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2-(2,2,2-trifluoroethyl)-3-(3,3,3-trifluoropropyl)succinamide (3); (2R,3S)—N-((3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(2,2,2-trifluoroethyl)-2-(3,3,3-trifluoropropyl)succinamide (4); (2R,3S)—N-((3S)-1-(2H3)Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (5); (2R,3S)—N-((3S)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (6);
 - 25 (2R,3S)—N-((3S)-8-methoxy-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (7); (2R,3S)—N-((3S)-8-fluoro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (8); (2R,3S)—N-((3S)-7-methoxy-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (9); (2R,3S)—N-((3S)-7-fluoro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (10); (2R,3S)—N-((3S)-8-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (11); (2R,3S)—N-((3S)-9-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-
 - 30

- trifluoropropyl)succinamide (12); (2R,3S)—N-((3S)-8-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (13); (2R,3S)—N-((3S)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (14); (2R,3S)—N-((3S)-8-cyano-9-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (15); (2R,3S)—N-((3S)-8,9-dichloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (16); (2R,3S)—N-((3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (17); (2R,3S)—N-((3S)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (18); (2R,3S)—N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (19); (2R,3S)—N-((3S)-8-Methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (20); or (2R,3S)—N-((3S)-9-((2-Methoxyethyl)amino)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (21).

8. The method of any one of claims 1-7, wherein said compound comprises:



9. The method of any one of claims 1-7, wherein said compound comprises:



10. The method of any one of claims 1-9, wherein said composition is administered at a dose of 4 mg.
11. The method of any one of claims 1-9, wherein said composition is administered at a dose of 6 or 8.4 mg.
- 5 12. The method of any one of claims 1-9, wherein said composition is administered at a dose of 0.3, 0.6, 1.2 or 2.4 mg.
13. The method of any one of claims 1-12, wherein said composition is administered once per week.
14. The method of any one of claims 1-12, wherein said composition is administered once every
10 two weeks.
15. The method of any one of claims 1-14, wherein said ACC tumor comprises tubular ACC, cribriform ACC, or solid ACC.
16. The method of any one of claims 1-15, wherein said ACC tumor comprises a Notch-activating mutation.
- 15 17. The method of claim 16, wherein said Notch-activating mutation comprises a Notch1 mutation, a Notch2 mutation, a Notch3 mutation, a Notch4 mutation, or a combination thereof.
18. The method of any one of claims 16-17, wherein said Notch-activating mutation functionally inactivates the negative regulatory region (NRR) of the Notch gene.
19. The method of any one of claims 16-18, wherein said Notch-activating mutation functionally
20 inactivates the PEST domain of the Notch gene.
20. The method of any one of claims 18-19, wherein said Notch-activating mutation comprises a sequence variant in the NRR domain, PEST domain, or combination thereof of a Notch gene.
21. The method of any one of claims 16-20, wherein said Notch-activating mutation comprises a gene rearrangement in the ectodomain of a Notch gene.
- 25 22. The method of claim 21, wherein said gene rearrangement removes most of the NRR.